

Supplement:  
**SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients**

**Authors:** Harold J. Manley<sup>1</sup>, Gideon N. Aweh<sup>1</sup>, Caroline M. Hsu<sup>2</sup>, Daniel E. Weiner<sup>2</sup>, Dana Miskulin<sup>2</sup>, Antonia M. Harford<sup>1</sup>, Doug Johnson<sup>1</sup>, Eduardo K. Lacson<sup>1,2</sup>

1. Dialysis Clinic Inc., Nashville, TN
2. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts

Table S1. COVID-19 infection and COVID-related hospitalization/death rates per 10,000 patient days and vaccine effectiveness between June 27 and October 2, 2021 in patients vaccinated during Delta dominant period.

	<b>Last Vaccination Status*</b>	<b>Person Days at Risk</b>	<b>Events within 30 days COVID-19 diagnosis</b>	<b>Rate per 10,000 days</b>	<b>Adjusted Hazard Ratio (95% CI)</b>	<b>Vaccine Effectiveness (95% CI)</b>
<b>COVID-19 infection</b>						
Unvaccinated	2660	274,527	217	7.9	Reference	Reference
Partially Vaccinated	467	41,541	24	5.8	0.73 (0.47,1.11)	27%
Fully Vaccinated	636	31,411	11	3.5	0.43 (0.24,0.79)	57%
BNT162b2/Pfizer	321	14,325	9	6.3	0.75(0.38,1.47)	25%
mRNA-1273/Moderna	268	14,315	1	0.7	0.09(0.01,0.62)	91%
Ad26.COV2.S/Janssen	47	2,771	1	3.6	0.48(0.07,3.47)	52%
<b>COVID-related hospitalization/death</b>						
Unvaccinated	2660	282,368	86	3.05	Reference	Reference
Partially Vaccinated	467	42,216	10	2.37	0.69(0.36,1.34)	31%
Fully Vaccinated	636	31,696	4	1.26	0.37(0.14,1.02)	63%
BNT162b2/Pfizer	321	14,595	4	2.74	0.79(0.29,2.16)	21%
mRNA-1273/Moderna	268	14,325	0	0.00	n/a	n/a
Ad26.COV2.S/Janssen	47	2,776	0	0.00	n/a	n/a

CI = confidence interval; n/a = not applicable; \* = Although patients can contribute time to any vaccination status, the N in the first column refers to patients' status at the end of follow-up. Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were  $\geq 14$  days after the first mRNA vaccine dose but  $< 14$  days after the 2nd mRNA vaccine dose; fully vaccinated patients includes all patients  $\geq 14$  days after the last vaccine dose.

Adjusted for age, days since full vaccination status, female, number of comorbidities, race (white = reference), congregational living (e.g., nursing home, long-term care facility), hemodialysis single pool Kt/V  $\geq 1.2$  or peritoneal dialysis weekly Kt/V  $\geq 1.7$ , albumin, Hepatitis B seroimmunity defined as hepatitis B surface antibody  $\geq 10$  mIU/mL, disability, diabetes, hypertension, peripheral vascular disease, thyroid disease, cancer, county rates for Biden voters and daily rate of COVID infection.

Table S2. Parameter hazard ratios against COVID-19 related hospitalization or death.

Parameter	pre-Delta variant period	Delta variant dominant period
	Hazard Ratio (95% Confidence Interval)	Hazard Ratio (95% Confidence Interval)
Unvaccinated	Reference	Reference
Partially Vaccinated	1.21 (0.77, 1.90)	0.79 (0.44, 1.42)
Fully vaccinated BNT162b2/Pfizer	<b>0.22 (0.07, 0.67)</b>	<b>0.17 (0.10, 0.31)</b>
Fully vaccinated mRNA-1273/Moderna	<b>0.08 (0.02, 0.30)</b>	<b>0.09 (0.05, 0.17)</b>
Fully vaccinated Ad26.COV2.S/Janssen	0.55 (0.12, 2.61)	<b>0.19 (0.08, 0.43)</b>
Weeks since full vaccination status	1.04 (0.93, 1.17)	<b>1.17 (1.11, 1.23)</b>
Age (per decade)	1.29 (0.82, 2.05)	0.94 (0.86, 1.04)
Female	<b>1.55 (1.10, 2.20)</b>	1.08 (0.83, 1.40)
Race - Black (reference = White)	1.03 (0.69, 1.54)	1.10 (0.82, 1.47)
Race - Other (reference = White)	1.22 (0.75, 1.99)	1.02 (0.70, 1.48)
Congregate living <sup>a</sup>	<b>2.12 (1.37, 3.28)</b>	<b>1.97 (1.44, 2.70)</b>
Albumin g/dL (continuous)	1.00 (0.69, 1.45)	<b>0.47 (0.37, 0.60)</b>
Hepatitis B surface antibody $\geq 10$ mIU/mL	0.70 (0.47, 1.03)	<b>0.67 (0.47, 0.95)</b>
History of failed transplant	0.49 (0.18, 1.33)	<b>0.44 (0.19, 0.99)</b>
Number of comorbidities	0.92 (0.81, 1.04)	1.08 (1.00, 1.18)
Diabetes	0.97 (0.66, 1.42)	<b>1.39 (1.03, 1.88)</b>
Hypertension	1.52 (0.88, 2.62)	1.16 (0.76, 1.77)

<sup>a</sup> = Residing in nursing home or long-term care facility; Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were  $\geq 14$  days after the first mRNA vaccine dose but  $< 14$  days after the 2nd mRNA vaccine dose; fully vaccinated patients includes all patients  $\geq 14$  days after the last vaccine dose.

Table S3. Parameter hazard ratios against COVID-19 related hospitalization or death in patients vaccinated during Delta variant dominant period.

Parameter	Hazard Ratio (95% Confidence Interval)
Unvaccinated	Reference
Partially Vaccinated	0.85 (0.44, 1.61)
Fully vaccinated BNT162b2/Pfizer	0.56 (0.10, 3.26)
Fully vaccinated mRNA-1273/Moderna	n/a
Fully vaccinated Ad26.COV2.S/Janssen	n/a
Weeks since full vaccination status	1.05 (0.79, 1.40)
Age (per decade)	0.91 (0.80, 1.03)
Female	1.40 (0.96, 2.04)
Race - Black (reference = White)	1.16 (0.77, 1.74)
Race - Other (reference = White)	1.22 (0.71, 2.10)
Congregate living <sup>a</sup>	<b>2.01 (1.27, 3.22)</b>
Albumin g/dL (continuous)	0.75 (0.52, 1.07)
Hepatitis B surface antibody $\geq 10$ mIU/mL	0.58 (0.16, 2.07)
History of failed transplant	0.50 (0.16, 1.60)
Number of comorbidities	1.13 (1.00, 1.28)
Diabetes	1.23 (0.81, 1.88)
Hypertension	1.39 (0.74, 2.64)

<sup>a</sup> = Residing in nursing home or long-term care facility; Unvaccinated includes patients who never received a vaccine or recipients of a single dose of a vaccine within 14 days of vaccine receipt; partially vaccinated includes patients who were  $\geq 14$  days after the first mRNA vaccine dose but  $< 14$  days after the 2nd mRNA vaccine dose; fully vaccinated patients includes all patients  $\geq 14$  days after the last vaccine dose

Figure S1. Cumulative percent COVID-19 breakthrough infections relative to days since full vaccination status overall (panel A) and by vaccine type (panel B)

